Compare SCYX & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | LFT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 35.8M |
| IPO Year | 2014 | 2012 |
| Metric | SCYX | LFT |
|---|---|---|
| Price | $2.97 | $3.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.67 | N/A |
| AVG Volume (30 Days) | ★ 59.4K | 15.3K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 31.83% |
| EPS Growth | ★ 61.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | $168.78 |
| Revenue Next Year | $977.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $3.76 |
| 52 Week High | $6.09 | $69.35 |
| Indicator | SCYX | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 26.17 | 41.54 |
| Support Level | $0.66 | N/A |
| Resistance Level | $4.15 | $5.83 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 4.17 | 2.78 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.